AGAlexey Golovanov

Alexey Golovanov

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Alexey Golovanov has a total of 77 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Mammalian Arachidonic Acid 15-Lipoxygenases: Fed-Batch Fermentation, Enzyme Purification and Functional Characterization

    by Vladislav Aksenov, Angelina V. Kurchatova, Alexey Golovanov, Veronika Ulasenko, Olga Zubkova, Alexander Zhuravlev, Ekaterina Makishvili, Nikolay E. Kushlinskii, Hartmut Kuhn, Igor Ivanov

    Background: Mammalian arachidonic acid lipoxygenases (ALOXs) are non-heme iron-containing enzymes that oxygenate polyunsaturated fatty acids (PUFAs) with at least two isolated double bonds to hydroperoxy derivatives. The patho-physiological roles of these enzymes in inflammatory, hyperproliferative, and neurological diseases have made them promising targets for pharmacological interventions. Unfortunately, the expression levels of ALOX isoforms in mammalian cells are very low, which makes functional characterization of native enzymes and the development of isoform-specific inhibitors challenging. Methods: Here, we developed a unifying experimental protocol for fed-batch fermentation of mammalian ALOX isoforms in a bioreactor, followed by purification of the recombinant proteins and their functional characterization. Results: Our methodological protocol allowed the preparation of mg amounts of catalytically active human ALOX15, mouse Alox15 and human ALOX15B. The purified proteins are suitable for high-throughput inhibitor screening assays but can also be used as antigens for the preparation of isoform-specific antibodies and for direct structural analyses. Antibodies cross-reacting with human ALOX15 and ALOX15B have been detected in the blood of patients suffering from colorectal cancer. Conclusions: Our functional ALOX data stresses the catalytic differences between mouse and human ALOX15 orthologs, and these catalytic peculiarities need to be considered when the results of mechanistic studies obtained in mouse models of human diseases are transferred to the human situation.

  • Open Access

    Structural Improvement of the Allosteric ALOX15 Inhibitor Octyl (N-(5-(1H-Indol-2-yl)-2-methoxyphenyl)sulfamoyl)carbamate

    by Viktor Gavrilyuk, Vladislav Aksenov, Kirill Petrov, Angelina V. Kurchatova, Dmitriy Bortnevskij, Alexander Zhuravlev, Alexey Golovanov, Hartmut Kuhn, Igor Ivanov

    Octyl (N-(5-(1H-indol-2-yl)-2-methoxyphenyl)sulfamoyl)carbamate has previously been characterized as substrate-specific inhibitor of the linoleic acid oxygenase activity of mammalian ALOX15 orthologs. Here we aimed at optimizing the inhibitory properties of this compound by three different chemical modifications: (i) replacement of the indole core by a phenylpyrrole; (ii) introduction of hydrophilic residues into the aliphatic hydrocarbon chain of the lead compound or by replacing this building block by a triethylene glycol moiety; (iii) replacement of the sulfamoylcarbamate group by a sulfonamide. The inhibitory potencies of the modified compounds for pure rabbit ALOX15 were quantified by in vitro inhibitory assays, and our data indicate that the replacement of the rigid indole core induced a partial loss in the inhibitor’s potency. The introduction of a hydrophilic group into the aliphatic hydrocarbon chain or its replacement by a triethylene glycol moiety improved the solubility of the compound in aqueous solution, but reduced the inhibitor potency by more than one order of magnitude. Finally, the replacement of the sulfamoylcarbamate moiety by sulfonamide improved the substrate selectivity of the inhibitor for rabbit and human ALOX15. The new compounds were highly potent for human and rabbit ALOX15, but did not inhibit human ALOX15B and were less effective for mouse Alox15 (ortholog specificity).

  • Synthesis and evaluation of the combined chemotherapeutic and photodynamic action of new Pt-complexes of natural chlorins

    by Petr V. Ostroverkhov, Anna D. Plutinskaya, Ksenia V. Luneva, Evgeniya O. Borzhitskaya, Polina E. Lavrinova, Nikolay D. Govorov, Aleksey B. Golovanov, Ekaterina S. Neryabova, Leonid Y. Martinov, Maxim N. Usachev, et al.

  • Open Access

    Scaffold Simplification Yields Potent Antibacterial Agents That Target Bacterial Topoisomerases

    by Lyubov Khudiakova, Kristina Komarova, Maxim Zhuravlev, Dmitry Deniskin, Alexey Golovanov, Artemiy Nichugovskiy, Kirill Babkin, Maria Zakharova, Mikhail Chudinov, Elizaveta Rogacheva, et al.

    This work describes the lead optimization of a promising class of antibacterial compounds, derived from a previously reported N-[4-(4-fluorophenoxy)phenyl]-6-(methylsulfonyl)-2,6-diazaspiro [3.4]octane-8-carboxamide (LK1819), through systematic scaffold simplification. A novel series of amide derivatives were designed and synthesized, exploring key structural variations, including the replacement of the diphenyl ether core with a biphenyl system. All compounds were evaluated for in vitro antibacterial activity against the ESKAPE panel of pathogens. The most potent simplified analogs demonstrated exceptional, broad-spectrum activity, with minimum inhibitory concentrations (MICs) that were 10 to 100 times lower than the control antibiotic ciprofloxacin against many strains. Mechanistic studies using a reporter system and enzymatic assays revealed that the compounds do not inhibit protein synthesis but disrupt DNA replication, exhibiting a dose-dependent inhibitory effect on bacterial topoisomerase I and DNA gyrase. The compounds showed moderate toxicity against human cell lines, consistent with their DNA-targeting mechanism, but cytotoxicity assays indicated a sufficient selectivity window. We conclude that scaffold simplification successfully yielded highly potent antibacterial agents with a defined mechanism of action, presenting a promising foundation for further development as antibiotics and potentially as anticancer agents.

  • Open Access

    Exploring allosteric properties of mammalian ALOX15: octyl ( N -(4-(benzofuran-2-yl)-2-methoxyphenyl)sulfamoyl)- and octyl ( N -(4-(1 H -indol-2-yl)-2-methoxyphenyl)sulfamoyl)carbamates as ALOX inhibitors

    by Viktor Gavrilyuk, Alejandro Cruz, Vladislav Aksenov, Danila Nurgaliev, Alexander Zhuravlev, Alexey Golovanov, José M. Lluch, Hartmut Kuhn, Igor Ivanov, ÀNgels González-Lafont

    Mammalian ALOX15 are allosteric enzymes but the mechanism of allosteric regulation remains a matter of discussion. Octyl (N-(5-(1H-indol-2-yl)-2-methoxyphenyl)sulfamoyl)carbamate inhibits the linoleate oxygenase activity of ALOX15 at nanomolar concentrations, but oxygenation of arachidonic acid is hardly affected. The mechanism of substrate selective inhibition suggests inter-monomer communication within the allosteric ALOX15 dimer complex, in which the inhibitor binding to monomer A induces conformational alterations in the structure of the active site of monomer B. Interactions of the NH-group of the indole moiety with the Fe(III)–OH− cofactor or of the SO2 group of the sulfocarbamate moiety with the side chain NH2 group of Gln596 may be important for proper inhibitor placement in the ALOX15 allosteric complex. Substitution of a H-bond donor to a H-bond acceptor (NH–O-exchange) impacts but does not eliminate the ability of the compound to inhibit preferentially the LA-oxygenase activity of ALOX15. In contrast, swapping the positions of CH3O- and NH groups at the 2-aryl moiety led to a loss of substrate selective inhibition. In silico docking studies and molecular dynamics-simulations using a dimeric allosteric ALOX15 model have shown that binding of the substrate molecule to ALOX15 monomer B may alter the structure of the monomer A-inhibitor complex forcing the inhibitor to adopt a different binding mode. Taken together, this data suggests the possibility of two-way communication between ALOX15 monomers during enzymatic catalysis.


  • Open Access

    Different Structures—Similar Effect: Do Substituted 5-(4-Methoxyphenyl)-1H-indoles and 5-(4-Methoxyphenyl)-1H-imidazoles Represent a Common Pharmacophore for Substrate Selective Inhibition of Linoleate Oxygenase Activity of ALOX15?

    by Alexander Zhuravlev, Alejandro Cruz, Vladislav Aksenov, Alexey Golovanov, José M. Lluch, Hartmut Kuhn, Àngels González-Lafont, Igor Ivanov

    Mammalian 15-lipoxygenases (ALOX15) are lipid peroxidizing enzymes that exhibit variable functionality in different cancer and inflammation models. The pathophysiological role of linoleic acid- and arachidonic acid-derived ALOX15 metabolites rendered this enzyme a target for pharmacological research. Several indole and imidazole derivatives inhibit the catalytic activity of rabbit ALOX15 in a substrate-specific manner, but the molecular basis for this allosteric inhibition remains unclear. Here, we attempt to define a common pharmacophore, which is critical for this allosteric inhibition. We found that substituted imidazoles induce weaker inhibitory effects when compared with the indole derivatives. In silico docking studies and molecular dynamics simulations using a dimeric allosteric enzyme model, in which the inhibitor occupies the substrate-binding pocket of one monomer, whereas the substrate fatty acid is bound at the catalytic center of another monomer within the ALOX15 dimer, indicated that chemical modification of the core pharmacophore alters the enzyme–inhibitor interactions, inducing a reduced inhibitory potency. In our dimeric ALOX15 model, the structural differences induced by inhibitor binding are translated to the hydrophobic dimerization cluster and affect the structures of enzyme–substrate complexes. These data are of particular importance since substrate-specific inhibition may contribute to elucidation of the putative roles of ALOX15 metabolites derived from different polyunsaturated fatty acids in mammalian pathophysiology.


  • Mutations of Triad Determinants Changes the Substrate Alignment at the Catalytic Center of Human ALOX5

    by Igor Ivanov, Alexey B. Golovanov, Cristián Ferretti, Miquel Canyelles-Niño, Dagmar Heydeck, Sabine Stehling, José M. Lluch, Àngels González-Lafont, Hartmut Kühn

    For the specificity of ALOX15 orthologs of different mammals the geometry of the amino acids Phe353, Ile418, Met419 and Ile593 (“triad determinants”) is important and mutagenesis of these residues altered the reaction specificity of these enzymes. Here we expressed wildtype human ALOX5 and its F359W/A424I/N425M/A603I mutant in Sf9 insect cells and characterized the catalytic differences of the two enzyme variants. We found that wildtype ALOX5 converted arachidonic acid mainly to 5(S)-HpETE. In contrast, 15(S)- and 8(S)-H(p)ETE were formed by the mutant enzyme. In addition to arachidonic acid, wildtype ALOX5 accepted EPA as substrate but C18 fatty acids were not oxygenated. The quadruple mutant also accepted linoleic acid, alpha- and gamma-linolenic acid as substrate. Structural analysis of the oxygenation products and kinetic studies with stereospecifically labeled 11(S)- and 11(R)-deutero linoleic acid suggested alternative ways of substrate orientation at the active site. In silico docking studies, molecular dynamics simulations and QM/MM calculations confirmed this hypothesis. These data indicate that “triad determinant” mutagenesis alters the catalytic properties of ALOX5 abolishing its leukotriene synthase activity but improving its biosynthetic capacity for pro-resolving lipoxins.


  • Effect of 20-hydroxy-(5Z,8Z,11Z,14Z)-eicosatetraenoic and Arachidonic Acids on Differentiation of Neurospora crassa

    by S. Yu. Filippovich, N. N. Gessler, G. P. Bachurina, E. A. Kharchenko, I. V. Ivanov, T. I. Sirotenko, A. B. Golovanov, T. A. Belozerskaya, N. V. Groza

    Comparative analysis of the influence of arachidonic acid and its derivatives, 3-hydroxy-(5Z,8Z,11Z,14Z)-eicosatetraenoic and 20-hydroxy-(5Z,8Z,11Z,14Z)-eicosatetraenoic acids, on the formation of...


  • Open Access

    Polar aromatic periphery increases agonist potency of spirocyclic free fatty acid receptor (GPR40) agonists inspired by LY2881835

    by Mikhail Krasavin, Alexey Lukin, Daria Bagnyukova, Nikolay Zhurilo, Aleksei Golovanov, Sergey Zozulya, Ihor Zahanich, Daniel Moore, Irina G. Tikhonova